Control group baseline characteristics
| Characteristic . | All patients, n = 111 . |
|---|---|
| Age, median (range), y | 44 (6-78) |
| Sex, n (%) | |
| Male | 73 (65.8) |
| Female | 38 (34.2) |
| Primary diagnosis (%) | |
| Hodgkin lymphoma | 51 (45.9) |
| Non-Hodgkin lymphoma | 60 (54.1) |
| Transplant, n (%) | |
| Autologous | 37 (33.3) |
| Allogeneic | 13 (11.7) |
| No transplant | 61 (55.0) |
| Included protocols | GRALE (NCT01555892) ALCI and ALASCER (NCT00062868) |
| Characteristic . | All patients, n = 111 . |
|---|---|
| Age, median (range), y | 44 (6-78) |
| Sex, n (%) | |
| Male | 73 (65.8) |
| Female | 38 (34.2) |
| Primary diagnosis (%) | |
| Hodgkin lymphoma | 51 (45.9) |
| Non-Hodgkin lymphoma | 60 (54.1) |
| Transplant, n (%) | |
| Autologous | 37 (33.3) |
| Allogeneic | 13 (11.7) |
| No transplant | 61 (55.0) |
| Included protocols | GRALE (NCT01555892) ALCI and ALASCER (NCT00062868) |